Your browser is no longer supported. Please, upgrade your browser.
RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-7.23 Insider Own1.40% Shs Outstand59.44M Perf Week-3.23%
Market Cap3.62B Forward P/E- EPS next Y-4.70 Insider Trans0.48% Shs Float54.34M Perf Month3.10%
Income-396.70M PEG- EPS next Q-1.72 Inst Own- Short Float11.84% Perf Quarter65.71%
Sales84.40M P/S42.85 EPS this Y27.20% Inst Trans-2.07% Short Ratio11.69 Perf Half Y5.02%
Book/sh12.60 P/B4.83 EPS next Y16.60% ROA-41.60% Target Price71.68 Perf Year0.53%
Cash/sh8.87 P/C6.86 EPS next 5Y17.20% ROE-48.80% 52W Range35.41 - 74.50 Perf YTD42.47%
Dividend- P/FCF- EPS past 5Y-18.10% ROI-61.10% 52W High-20.75% Beta2.51
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin94.80% 52W Low66.73% ATR2.69
Employees610 Current Ratio6.80 Sales Q/Q118.60% Oper. Margin- RSI (14)55.42 Volatility3.87% 4.01%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.80% Profit Margin- Rel Volume0.63 Prev Close60.85
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 AMC Payout- Avg Volume550.29K Price59.04
Recom1.90 SMA200.84% SMA5013.46% SMA20014.59% Volume248,466 Change-2.97%
Aug-02-19Resumed Wedbush Outperform $75
Mar-27-19Upgrade Morgan Stanley Equal-Weight → Overweight $68 → $83
Feb-22-19Resumed Raymond James Outperform $80
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18Upgrade Citigroup Sell → Neutral
Sep-10-18Initiated Morgan Stanley Equal-Weight $92
Jun-21-18Downgrade Credit Suisse Outperform → Neutral
May-11-18Upgrade Barclays Equal Weight → Overweight $62 → $74
May-10-18Initiated Goldman Neutral $63
Apr-18-18Upgrade SunTrust Hold → Buy
Mar-22-18Resumed Piper Jaffray Overweight $67
Feb-21-18Reiterated Stifel Buy $85 → $74
Jan-22-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Initiated Credit Suisse Outperform $67
Dec-05-17Reiterated Barclays Equal Weight $60 → $62
Dec-04-17Upgrade Jefferies Hold → Buy
Sep-14-17Upgrade Wedbush Neutral → Outperform $62
Aug-23-17Downgrade SunTrust Buy → Hold $55
Aug-17-17Initiated Evercore ISI In-line $63
Aug-08-17Reiterated H.C. Wainwright Neutral $72 → $75
Feb-21-20 08:30AM  Ultragenyx to Present at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-18-20 11:20PM  Edited Transcript of RARE earnings conference call or presentation 13-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-14-20 09:18AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-13-20 04:01PM  Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update GlobeNewswire
Feb-06-20 04:01PM  Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update GlobeNewswire
Feb-05-20 05:19AM  How Should Investors Feel About Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Pay? Simply Wall St.
Jan-16-20 07:22AM  The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics Benzinga
Jan-15-20 04:01PM  GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome GlobeNewswire
Jan-14-20 08:53AM  Ultragenyx Provides Preliminary Crysvita 2019 Revenues Zacks +6.68%
Jan-13-20 10:14AM  Ultragenyx's Gene Therapy Positive in Genetic Disorder Study Zacks +6.60%
08:10AM  Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance GlobeNewswire
08:00AM  Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Jan-10-20 07:13AM  The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga +23.39%
Jan-09-20 04:01PM  Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-19-19 08:30AM  Ultragenyx to Present at 38 Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-18-19 08:30AM  Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma GlobeNewswire
Dec-10-19 09:11PM  Do Hedge Funds Love Ultragenyx Pharmaceutical Inc (RARE)? Insider Monkey
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
11:31AM  Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 10:15AM  Companies Like Ultragenyx Pharmaceutical (NASDAQ:RARE) Are In A Position To Invest In Growth Simply Wall St. +6.18%
Nov-26-19 08:30AM  Ultragenyx to Present at Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-09-19 10:43AM  Edited Transcript of RARE earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-08-19 10:02AM  After sons rare disease diagnosis, father finds hope through film festival American City Business Journals
08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-06-19 11:00AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3 Zacks -5.87%
Nov-05-19 05:35PM  Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM  Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Oct-30-19 08:30AM  Ultragenyx to Host Conference Call for Third Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Oct-28-19 10:32AM  Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-26-19 02:55PM  Were Hedge Funds Right About Dumping Ultragenyx Pharmaceutical Inc (RARE)? Insider Monkey
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
10:19AM  Those Who Purchased Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Three Years Ago Have A 34% Loss To Show For It Simply Wall St.
Oct-15-19 10:57AM  Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA Zacks
Oct-14-19 08:30AM  Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders GlobeNewswire
Oct-02-19 08:31AM  Ultragenyx Gets FDA Approval for Label Expansion of Crysvita Zacks
08:30AM  Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit GlobeNewswire
Sep-30-19 08:30AM  Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) GlobeNewswire
Sep-11-19 03:15PM  Ultragenyx Pharmaceutical Inc (RARE) President & CEO Emil D Kakkis Bought $218,150 of Shares GuruFocus.com
11:37AM  Ultragenyx to Submit sBLA for Label Expansion of Crysvita Zacks
Sep-10-19 09:00AM  Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Sep-04-19 09:42AM  Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA Zacks -12.15%
04:00AM  Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia GlobeNewswire
Sep-03-19 12:38PM  Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Trading At A 36% Discount? Simply Wall St. -5.84%
08:30AM  GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 GlobeNewswire
Aug-31-19 09:32AM  Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound? Zacks
Aug-30-19 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Aug-23-19 07:36AM  Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues Zacks
Aug-15-19 04:35PM  This Biotech Stock Just Roped In A New Partner And A Potential Buyout Investor's Business Daily
Aug-14-19 08:30AM  Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome GlobeNewswire
Aug-13-19 08:30AM  Ultragenyx to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-12-19 10:59AM  Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View Zacks
Aug-10-19 11:18AM  Edited Transcript of RARE earnings conference call or presentation 1-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-02-19 10:28AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2 Zacks -7.89%
01:24AM  Ultragenyx Pharmaceutical Inc (RARE) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 05:55PM  Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update GlobeNewswire
08:30AM  Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders GlobeNewswire
Jul-25-19 10:34AM  Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-23-19 08:30AM  Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Jul-17-19 10:20AM  Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is A Financially Healthy Company Simply Wall St.
Jul-15-19 08:30AM  Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D. GlobeNewswire
Jul-01-19 09:26AM  Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status Zacks
Jun-24-19 09:59AM  Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more American City Business Journals
Jun-20-19 09:01AM  Ultragenyx & Arcturus Therapeutics Expand Existing Agreement Zacks
Jun-19-19 03:30PM  Heres What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE) Insider Monkey
08:30AM  Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases GlobeNewswire
Jun-17-19 08:30AM  Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer GlobeNewswire +6.54%
Jun-11-19 04:40PM  'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases American City Business Journals
Jun-05-19 09:30AM  Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound? Zacks
May-31-19 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
May-29-19 04:01PM  Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIOs 2019 Henri A. Termeer Biotechnology Visionary Award GlobeNewswire
May-23-19 02:49PM  Is Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Paid At A Competitive Rate? Simply Wall St.
May-11-19 02:05PM  Edited Transcript of RARE earnings conference call or presentation 6-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-10-19 08:30AM  Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference GlobeNewswire
May-07-19 08:56AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1 Zacks -6.96%
12:43AM  Ultragenyx Pharmaceutical Inc (RARE) Q1 2019 Earnings Call Transcript Motley Fool
May-06-19 04:14PM  Ultragenyx: 1Q Earnings Snapshot Associated Press
04:01PM  Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update GlobeNewswire
May-03-19 09:51AM  What's in Store for Catalyst Pharma (CPRX) Q1 Earnings? Zacks
07:54AM  Factors Expected to Influence Qorvo (QRVO) in Q4 Earnings Zacks
May-02-19 04:39PM  Protalix (PLX) to Report Q1 Earnings: What's in the Cards? Zacks
May-01-19 12:16PM  Did Hedge Funds Drop The Ball On Ultragenyx Pharmaceutical Inc (RARE) ? Insider Monkey
Apr-30-19 08:30AM  Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Apr-29-19 04:41PM  Arcus (RCUS) to Report Q1 Earnings: What's in the Cards? Zacks
10:53AM  Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards? Zacks
10:31AM  Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-24-19 09:11AM  5 Biotech Stocks Defying the Medicare-for-All Scare Zacks
Apr-22-19 12:28AM  Health Care Digest: Attacking a deadly infant virus, Medicaid's smoking gun and exporting genetic expertise American City Business Journals
Apr-17-19 08:14AM  Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA Zacks -5.28%
Apr-16-19 08:30AM  Ultragenyx Announces UX007 Granted Fast Track Designation and Rare Pediatric Disease Designation by U.S. FDA for Treatment of Long-Chain Fatty Acid Oxidation Disorders GlobeNewswire -5.45%
Apr-15-19 08:43AM  Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-11-19 08:30AM  Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 17 in New York GlobeNewswire
Apr-10-19 04:44PM  Global X Launches GNOM ETF to Tap Booming Genomics Space Zacks
Mar-27-19 07:19AM  Have Insiders Been Selling Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares? Simply Wall St.
Mar-26-19 08:30AM  Ultragenyx Announces Approval of Crysvita® (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children GlobeNewswire
07:15AM  New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-21-19 09:30AM  Why Is Ultragenyx (RARE) Up 12.4% Since Last Earnings Report? Zacks
Mar-11-19 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Feb-26-19 07:13PM  Ultragenyx Announces Pricing of Public Offering of Common Stock GlobeNewswire
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing DTX701 that is in preclinical development for Wilson disease; UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huizenga Theodore AlanSVP, Controller and PAOJan 14Sale61.001,00061,00015,946Jan 15 01:08 PM
Sharp ShaliniCFO & Executive Vice PresidentSep 16Option Exercise5.5431,843176,31799,089Sep 17 07:25 PM
KAKKIS EMIL DPresident & CEOSep 11Buy43.635,000218,150472,479Sep 11 12:35 PM
Parschauer Karah HerdmanEVP and General CounselJun 24Sale61.501,22675,39917,650Jun 24 09:16 PM
Parschauer Karah HerdmanEVP and General CounselJun 21Sale63.011,48993,82218,876Jun 24 09:16 PM
Parschauer Karah HerdmanEVP and General CounselApr 29Sale68.3046831,96419,580Apr 30 06:32 PM
Sharp ShaliniCFO & Executive Vice PresidentMar 18Option Exercise6.8612,00082,32081,157Mar 20 04:26 PM
Sharp ShaliniCFO & Executive Vice PresidentMar 18Sale70.0014,8001,036,00066,357Mar 20 04:26 PM